A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)



Status:Completed
Conditions:Renal Impairment / Chronic Kidney Disease, Renal Impairment / Chronic Kidney Disease, Anemia
Therapuetic Areas:Hematology, Nephrology / Urology
Healthy:No
Age Range:18 - 99
Updated:10/14/2018
Start Date:October 31, 2013
End Date:June 15, 2015

Use our guide to learn which trials are right for you!

A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.

This study will be conducted in approximately 228 subjects with anemia associated with CKD
who are not on dialysis. Two groups of subjects will be enrolled into the study: Group 1:
recombinant human erythropoietin (rhEPO) naive subjects; Group 2: rhEPO users, who are
currently receiving rhEPO. Subjects who are rhEPO naive will be randomized to receive either
GSK1278863 once daily (QD) or rhEPO in a 3:1 fashion; subjects who are receiving an rhEPO
before enrolling (rhEPO users) will be randomized in a 1:1 fashion to GSK1278863 QD or to the
control arm. For those randomized to the control arm, the decision around whether the subject
requires rhEPO, the selection of the type of rhEPO (if needed) and the choice of rhEPO dose
to achieve and maintain Hgb concentrations within the target range should be based on
Investigator clinical judgment, with the historical rhEPO dose and the current Hgb value
being considered. The study consists of a screening phase of at least 4 weeks, a 24-week
treatment phase and a follow-up visit that will occur approximately 4 weeks after completing
treatment. It is anticipated that the data generated will enable selection of the starting
dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials.


Inclusion Criteria:

- Age: >=18 years of age. (Week -4 verification only)

- Gender: Female and male subjects. (Week -4 verification only) Females: If of
childbearing potential, must agree to use one of the approved contraception methods,
from Screening until completion of the Follow-up Visit OR Of non-childbearing
potential defined as pre-menopausal females with a documented tubal ligation,
hysterectomy, or oophorectomy; or postmenopausal defined as 12 months of spontaneous
amenorrhea. Females on hormone replacement therapy (HRT) whose menopausal status is in
doubt will be required to use one of the approved contraception methods if they wish
to continue their HRT during the study. Otherwise they must discontinue HRT to allow
confirmation of post-menopausal status prior to study enrolment.

- Corrected QT interval (QTc): Bazett's Correction of QT Interval (QTcB) <470
milliseconds (msec) or QTcB <480 msec in subjects with bundle branch block. There is
no QTc criterion for subjects with a predominantly paced rhythm.

- CKD stage: Kidney Disease Outcomes Quality Initiative (KDOQI) CKD stages 3/4/5 defined
by electronic estimated glomerular filtration rate (eGFR) using the CKD Epidemiology
Collaboration (CKD-EPI) formula.

- Hgb: Group 1 (rhEPO naïve): Baseline Hgb of 8.0-11.0 g/dL (inclusive) (USA sites only:
8.0-10.0 g/dL, inclusive); Group 2 (rhEPO users): Baseline Hgb of 9.0-11.5 g/dL
(inclusive) (USA sites only: 9.0-10.5, inclusive).

- Stable rhEPO dose for rhEPO users: Group 2 subjects must be using the same rhEPO
(epoetins or their biosimilars, or darbepoetin) with total weekly doses that varied by
no more than 50% during the 4 weeks prior to Week -4. At Day 1 (randomization),
confirm that total weekly doses varied by no more than 50% during the screening
period.

- Oral iron therapy: If on oral iron, then doses must not be changed for the 4 weeks
prior to Week -4, during the screening phase, and through the first 4 weeks after
Randomization.

Exclusion Criteria:

- Dialysis: On dialysis or planning to initiate dialysis during the study.

- Renal transplant: Pre-emptive or scheduled renal transplant.

- High rhEPO dose: An epoetin dose of >=360 IU/kg/week intravenous (IV) or >=250
IU/kg/week subcutaneous (SC) or darbepoetin dose of >=1.8 microgram per kilogram per
week (mcg/kg/week) IV or SC within the prior 8 weeks through Day 1 (randomization).

- Use of methoxy polyethylene glycol epoetin beta within the prior 8 weeks through Day 1
(randomization).

- IV iron therapy: Use of IV iron for 4 weeks prior to Screening Week -4, during the
screening phase, and through the first 4 weeks after Randomization

- Vitamin B12: Below the lower limit of the reference range (may rescreen in a minimum
of 8 weeks).

- Folate: <2.0 nanogram per millilitre (ng/mL) (<4.5 nanomoles per liter [nmol/L]) (may
rescreen in a minimum of 4 weeks).

- Ferritin: <40 ng/mL (<40 mcg/L).

- Transferrin saturation (TSAT): Below the lower limit of the reference range

- Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to
Screening through Day 1 (randomization).

- Stroke or transient ischemic attack: Within the 8 weeks prior to Week -4 Screening
through Day 1 (randomization).

- Heart failure: Class III/IV heart failure as defined by the New York Heart Association
(NYHA) functional classification system diagnosed prior to Week -4 Screening through
Day 1 (randomization), symptomatic right heart failure diagnosed prior to Week -4
Screening through Day 1 (randomization).

- Uncontrolled hypertension: Defined as diastolic blood pressure (DBP) >100 mmHg or
systolic blood pressure (SBP) >170 mmHg at Week -4 and reconfirmed at Day 1.

- Thrombotic Disease: History of thrombotic disease (e.g., venous thrombosis such as
deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset
or worsening limb ischemia requiring intervention), except vascular access thrombosis
within the 8 weeks prior to Week -4 Screening through Day 1 (randomization).

- Ophthalmology disease: Meeting any ophthalmologic-related exclusion criteria
determined at the Screening ophthalmology exam.

- Inflammatory disease: Active chronic inflammatory disease that could impact
erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis,
celiac disease) diagnosed prior to Week -4 Screening through Day 1 (randomization).

- Hematological disease: Any hematological disease including those affecting platelets,
white or red blood cells (e.g. sickle cell anemia, myelodysplastic syndromes,
hematological malignancy, myeloma, hemolytic anemia and thalassemia), coagulation
disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other
cause of anemia other than renal disease diagnosed prior to Week -4 Screening through
Day 1 (randomization).

- Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the
exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening
of abnormal liver function tests [alanine transaminase (ALT) or aspartate transaminase
(AST) >2.0 x upper limit of normal (ULN) or total bilirubin >1.5 x ULN]; or other
hepatic abnormalities that in the opinion of the investigator would preclude the
subject from participation in the study.

- Major surgery: Major surgery (excluding vascular access surgery) within the prior 8
weeks, during the Week -4 Screening phase or planned during the study.

- Transfusion: Blood transfusion within the prior 8 weeks, during the Week -4 Screening
phase or an anticipated need for blood transfusion during the study.

- Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or
esophageal ulcer disease OR clinically significant GI bleeding within the 8 weeks
prior to Week -4 Screening through Day 1 (randomization).

- Acute infection: Clinical evidence of acute infection or history of infection
requiring IV antibiotic therapy within the 8 weeks prior to Week -4 Screening through
Day 1 (randomization).

- Malignancy: Subjects with a history of malignancy within the prior 5 years, who
receiving treatment for cancer, or who have a strong family history of cancer (e.g.,
familial cancer disorders); with the exception of squamous cell or basal cell
carcinoma of the skin that has been definitively treated prior to Week -4 Screening
through Day 1 (randomization).

- Severe allergic reactions: History of severe allergic or anaphylactic reactions or
hypersensitivity to excipients in the investigational product (see GSK1278863 IB for
list of excipients and rhEPO (refer to local product labelling for details).

- Drugs and supplements: Use of any prescription or non-prescription drugs or dietary
supplements that are prohibited from Week -4 Screening until the Follow-up Visit.

- Prior investigational product exposure: The Subject has participated in a clinical
trial and has received an experimental investigational product within the prior 30
days from Week -4 Screening through Day 1 (randomization).

- Other Conditions: Any other condition, clinical or laboratory abnormality, or
examination finding that the Investigator considers would put the subject at
unacceptable risk.

- Patient participation: Unwillingness or inability of the subject to follow the
procedures or lifestyle or dietary restrictions outlined in the protocol.

- Pregnancy or Lactation: Pregnant females as determined by positive urine human
chorionic gonadotropin (hCG) test OR women who are lactating at Week -4 Screening or
during the trial.
We found this trial at
26
sites
Salt Lake City, Utah 84132
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Azusa, California 91702
?
mi
from
Azusa, CA
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18105
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Charlotte, North Carolina 28203
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Corsicana, Texas 75110
?
mi
from
Corsicana, TX
Click here to add this to my saved trials
Evergreen Park, Illinois 60805
?
mi
from
Evergreen Park, IL
Click here to add this to my saved trials
Farmington, Missouri 63640
?
mi
from
Farmington, MO
Click here to add this to my saved trials
Knoxville, Tennessee 37916
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
La Mesa, California 91942
?
mi
from
La Mesa, CA
Click here to add this to my saved trials
Laguna Hills, California 92653
?
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Lauderdale Lakes, Florida 33313
?
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
Liverpool, New South Wales 2170
?
mi
from
Liverpool,
Click here to add this to my saved trials
Los Angeles, California 90025
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Los Angeles, California 90025
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Macon, Georgia 31201
?
mi
from
Macon, GA
Click here to add this to my saved trials
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Pembroke Pines, Florida 33028
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Peoria, Arizona 85381
?
mi
from
Peoria, AZ
Click here to add this to my saved trials
San Antonio, Texas 78258
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
San Diego, California 92111
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Dimas, California 91773
?
mi
from
San Dimas, CA
Click here to add this to my saved trials
Savannah, Georgia 31405
?
mi
from
Savannah, GA
Click here to add this to my saved trials
Shreveport, Louisiana 71103
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
Temple, Texas 76508
?
mi
from
Temple, TX
Click here to add this to my saved trials
Uniontown, Pennsylvania 15401
?
mi
from
Uniontown, PA
Click here to add this to my saved trials
West Hills, California 91307
?
mi
from
West Hills, CA
Click here to add this to my saved trials